Abstracts tagged "rheumatologic practice"

Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting
Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting
More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares
Dinesh Khanna¹, Puja Khanna², Chris Storgard³, Scott Baumgartner⁴ and Robert Morlock⁵, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, San Diego, CA, ⁵Ardea Bioscience, San Diego, CA
Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…
Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting
Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries
Jasvinder A. Singh¹, Chris Storgard², Scott Baumgartner³ and Robert Morlock⁴, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²4939 Directors Place, Ardea Bioscience, San Diego, CA, ³Ardea Biosciences, San Diego, CA, ⁴Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting
A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout
Michael A. Becker¹, David Fitz-Patrick², Chris Storgard³, Matt Cravets⁴ and Scott Baumgartner⁵, ¹Medicine, University of Chicago, Chicago, IL, ²East-West Medical Research Institute, Honolulu, HI, ³4939 Directors Place, Ardea Bioscience, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Ardea Biosciences, San Diego, CA
Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…
Abstract Number: 1189 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study
Scott Baumgartner¹, Hyon Choi^2,3, Nicola Dalbeth⁴, David Fitz-Patrick⁵, Matt Cravets⁶ and Chris Storgard⁷, ¹Ardea Biosciences, San Diego, CA, ²Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Auckland District Health Board, Auckland, New Zealand, ⁵East-West Medical Research Institute, Honolulu, HI, ⁶Ardea Biosciences, Inc., San Diego, CA, ⁷4939 Directors Place, Ardea Bioscience, San Diego, CA
Background/Purpose: Allopurinol is the first-line urate-lowering therapy (ULT) for most people with gout, but target serum uric acid (sUA) levels of 200-300 >300-400 >400-500 >500-600…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].